|
|
 |
|
Viewing report
|
|
|
|
OTC Distribution in Europe: Driving the Recovery - New 18 Country Study
James Dudley Management, Jan 2010, Pages: 460
It defines and explores the main themes of change running through the European region and shows how they will influence the channel strategies for manufacturers’ of non-prescription and OTC self-medication as well associated consumer healthcare products.
It provides a wealth of knowledge covering 18 European markets together with insights into an increasingly competitive and complex marketing channel structure from a highly respected healthcare strategy consultant
James W. Dudley
This is the seventh edition of James W Dudley's highly regarded 18 country consultancy study - OTC Distribution in Europe. This expanded 2010 edition is the largest and most up to date strategic analysis of the supply network serving the non-prescription pharmaceuticals and OTC Self-medication in Europe with over 460 pages and 200 graphs, tables & figures.
OTC Distribution in Europe is a study of the factors driving change and presenting challenges and opportunities to manufacturers. It includes analysis and discussion of European and national statutory and regulatory developments; healthcare supply chain economics; evolving formal and informal channel structures; distribution channel competitors’ market shares, linkages and groupings.
OTC Distribution in Europe is an exploration of changes in manufacturer, retail customer and consumer and patient needs and the unfolding strategies required by healthcare companies to adapt and lead Europe’s self-medication markets. The 2010 study provides insights and understanding of inter-channel rivalries between pharmacy and the mass market operators and the need for retail pharmacy chains or voluntary groups to force the pace of innovation. This is needed to challenge emerging competing channels including supermarkets, mail order pharmacies and the Internet.
OTC Distribution in Europe provides up-to-date statistics, analysis, insights, discussion and opinions regarding the historic, present and future challenges and opportunities for the European non-prescription and OTC self medication market together with consumer healthcare and pharmaceutical market sizes trends, pricing and distributor market shares
Executive Summary
In 2010 European consumers are expected to purchase nearly $37.5 billion worth of non-prescription OTC medicines for self-medication representing around 36% of world demand. Accounting for 16% of retail pharmaceutical business in the region non-prescription self-medication is an important business category for both manufacturers and retailers.
Yet a number of major factors are coming into play which will influence the competitive environment for the consumer healthcare industry. Among these are the restructuring of the pharmaceutical supply chain, continued deregulation of retail channels, the growing importance of retail pharmacy groupings and mass market chains and the expansion of products licensed for sale in non-pharmacy outlets. These factors together will have a major impact on how manufacturers plan their strategies over the next few years.
“Change that will reshape the structure of the supply chain, focus buyer power and as a consequence present suppliers with new strategic challenges. The aim of this seventh study into OTC Distribution in Europe is to explore change and to provide thoughts on how to anticipate unfolding threats and opportunities”.
OTC Medicine Manufacturers will have to find strategic responses at both national and international levels to a number of critical issues some of which include:
- Future processes of deregulation of the pharmacy supply chain in the light of revised actions from the European Commission and the judgements by the - European Court of Justice affecting pharmacy ownership in Germany, France, Spain, Austria and Sweden
- Continuing concentration of pharmaceutical wholesaler’s buying power and vertical integration into retailing and logistics across European borders
- The expansion of a Europe-wide retail pharmacy footprint of ‘virtual’ and wholly owned chains connected to a handful of key wholesalers
- Recovery prospects for the non-prescription sector in Western Europe and its future in Eastern States in the light of healthcare reforms and the maturity of some core categories leading to changes to industry structures with an increasing shift to brand driven consumer marketing cultures
- The ambitions of mass market grocery and chain discount drugstore operators to enter the lucrative consumer health market through GSL brands and pharmacy and OTC unit in-plants
- The expansion of international retailers from Central and Eastern Europe into the European consumer health and beauty markets The spread of pharmacy chains and the introduction of general sale lists(GSL) to the Nordic Region
- The continuing legacy of reforms in Europe’s largest market, Germany, especially the impact on consumer confidence and perceptions of non-prescription medicines following the abolition of reimbursement for and resale price maintenance on OTC medicines, legalization of mail order and Internet marketing of pharmaceuticals and the benefits and costs of partial deregulation of pharmacy ownership – especially in terms of increased pharmacy numbers, improved profitability and the surge in affiliations to voluntary or virtual pharmacy chains
|
|
|
|
